Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Virios Therapeutics Inc (VIRI)

Virios Therapeutics Inc (VIRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,188
  • Shares Outstanding, K 19,258
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,300 K
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.15
Trade VIRI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.06 on 02/29/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 270.18% ( -483.49%)
  • Historical Volatility 134.04%
  • IV Percentile 49%
  • IV Rank 13.05%
  • IV High 1,389.95% on 04/15/24
  • IV Low 102.10% on 01/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 535
  • Open Int (30-Day) 528

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3602 +27.26%
on 03/26/24
0.5800 -20.97%
on 04/02/24
-0.0114 (-2.43%)
since 03/25/24
3-Month
0.2790 +64.30%
on 03/05/24
0.6288 -27.10%
on 03/22/24
+0.0333 (+7.83%)
since 01/25/24
52-Week
0.2790 +64.30%
on 03/05/24
2.4200 -81.06%
on 07/14/23
-0.5116 (-52.74%)
since 04/25/23

Most Recent Stories

More News
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia

VIRI : 0.4583 (+7.78%)
AGN : 193.02 (+0.02%)
LLY : 726.21 (-0.82%)
PFE : 25.42 (-3.24%)
GPS : 20.13 (+0.10%)
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics, Inc. Announces Closing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.4583 (+7.78%)
Pre-Market Brief: Stocks Mixed Ahead Of FOMC Meeting

December S&P 500 futures (ESZ22) are moderately down -0.08% this morning after three major US benchmark indices rebounded from 9-week lows to close higher during the regular session as market participants...

ESZ22 : 3,871.47s (-0.66%)
F : 12.74 (-1.62%)
GM : 45.55 (+1.04%)
VIRI : 0.4583 (+7.78%)
ENVX : 5.84 (-2.99%)
CGNX : 39.29 (-0.61%)
CHNG : 27.49 (+0.26%)
UNH : 494.59 (+1.50%)
Virios Therapeutics, Inc. Announces Pricing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics, Inc. Announces Proposed Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.4583 (+7.78%)
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.4583 (+7.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Virios Therapeutics Inc. is a biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics Inc. is based in Alpharetta, Georgia.

See More

Key Turning Points

3rd Resistance Point 0.5160
2nd Resistance Point 0.4953
1st Resistance Point 0.4603
Last Price 0.4583
1st Support Level 0.4046
2nd Support Level 0.3839
3rd Support Level 0.3489

See More

52-Week High 2.4200
Fibonacci 61.8% 1.6021
Fibonacci 50% 1.3495
Fibonacci 38.2% 1.0969
Last Price 0.4583
52-Week Low 0.2790

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar